Table 1– Baseline characteristics of study participants
Study participants
Subjects n17
Age yrs10.3±3.4
Females/males n11/8
Pseudomonas aeruginosa +ve3
Pancreatic insufficient %95
ΔF508/δF508 %37
ΔF508 compound heterozygous %21
FVC % pred97.6±11.4 (82.5–114.1)
FVC z-score-0.09±0.9 (-0.5–0.3)
FEV1 % pred90.7±9.1 (80.00–109.78)
FEV1 z-score-0.8±0.7 (-1.1–-0.5)
FEV1/FVC %81.5±7.9 (77.74–85.22)
FEV1/FVC z-score-0.009±5.5 (-2.6–2.6)
FEF25–75% % pred76.9±20.0 (51.7–119.2)
FEF25–75% z-score-1.1±0.9 (-1.6–-0.6)
  • Data are presented as mean±sd and 95% confidence interval, unless otherwise stated. Pseudomonas aeruginosa +ve: defined as more than two positive cultures in the previous year and/or currently on inhaled anti-pseudomonal therapy. % predicted spirometry values were calculated using the Stanojevic et al. 13 reference equations. ΔF508: deletion of phenylalanine 508 mutation of cystic fibrosis transmembrane conductance regulator; FVC: forced vital capacity, FEV1: forced expiratory volume in 1 s; FEF25–75%:forced expiratory flow at 25–75% of FVC; % pred: % predicted.